Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19641917 | 0.90 | CNR1 (0.44) | JAK2RIPK1ANO1P2RY14LMNA | |
| SCHEMBL19641910 | 0.90 | CNR2 (0.37) | KDM5AKDM4CKDM5BJAK2RIPK1 | |
| SCHEMBL19641895 | 0.89 | LMNA (0.39) | KDM5AKDM4CKDM5BALDH1A1RAB9A | |
| SCHEMBL19656285 | 0.89 | CACNA1B (0.45) | CACNA1BRIPK1ANO1POLBMAPT | |
| SCHEMBL19641889 | 0.88 | HPGDS (0.42) | ALDH1A1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL19641943 | 0.88 | P2RY14 (0.47) | JAK2RIPK1P2RY14DHODH | |
| SCHEMBL19641960 | 0.88 | GAA (0.38) | CACNA1BJAK2RIPK1P2RY14GAA | |
| SCHEMBL19641924 | 0.87 | EGLN2 (0.43) | — | |
| SCHEMBL19641966 | 0.86 | P2RY14 (0.36) | KDM4CJAK2ALDH1A1RIPK1P2RY14 | |
| SCHEMBL29727663 | 0.86 | WDR5 (0.35) | CACNA1BJAK2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | claimed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | claimed |
| EP-3464246-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | claimed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | claimed |
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3464246-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | SLC1A1, SLC1A3, SLC1A2 | CACNA1B 665/4885KDM4A 1605/4885KDM5A 1895/4885 |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | CACNA1B 665/4885KDM4A 1605/4885KDM5A 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.